Our experience with Logest-low dosage oral contraceptive from Schering

J. Georgievska, S. Georgieva, J. Tofoski, S. Popovska, G.Georgievski

Clinic for Gynaecology and Obstetrics, Medical faculty-Skopje, Republic of Macedonia

Objectives:The aim of this study was to evaluate the contraceptive efficiency of low dosage oral contraceptive Logest from Schering, which consists of 20µg ethinylestradiol and 75 µg gestoden.
Materials and Methods: The study population consisted of 111 healthy women, between 20-50 years old.They used Logest only as the oral contraceptive. They had to fill up a questionnaire.
Results: From 111 women after six month 73(67%) continued to use Logest. After three and six months there were no significant changes in laboratories evaluations, as in the quantity of withdrawal bleeding.
After three months in 106 women (95,4%) there were no significant changes in the body weight and after six months in 68(88%) of the women. Adverse effects of Logest were: intermenstrual bleeding, headache, vomiting etc.
Conclusions: The contraceptive efficiency of Logest is exellent, because there was no case of pregnancy in the study population. There were no significant changes in laboratories analyses.The body weight remained unchanged in the most of the women. There are numerous non-contraceptive benefits of Logest in the treatment of premenstrual syndrome, dysmenorrhoea, acne, benign ovarian cysts etc.